Adage Capital Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Adage Capital Partners’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-500,000	Closed	-$7.88M	–	949
2023 Q3	$7.88M	Buy	500,000 +100,000	+25%	+$1.8M	0.02%	611
2023 Q2	$7.78M	Hold	400,000	–	–	0.02%	609
2023 Q1	$11.3M	Hold	400,000	–	–	0.03%	590
2022 Q4	$11.7M	Buy	400,000 +150,000	+60%	+$4.77M	0.03%	596
2022 Q3	$6.61M	Hold	250,000	–	–	0.02%	743
2022 Q2	$11.1M	Buy	+250,000	New	+$11.5M	0.03%	643
2018 Q3	–	Sell	-50,000	Closed	-$3.78M	–	769
2018 Q2	$3.78M	Buy	+50,000	New	+$3.15M	0.01%	669
2016 Q3	–	Sell	-20,000	Closed	-$776K	–	736
2016 Q2	$776K	Buy	+20,000	New	+$833K	﹤0.01%	665

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Adage Capital Partners's EGRX Position: Q4 2023 in Review

Adage Capital Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 500,000 shares — an estimated $7.88M sold.

Adage Capital Partners first reported a position in EGRX in Q2 2016 and held it in 8 quarters. The position peaked at $11.7M in Q4 2022. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

Adage Capital Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
Adage Capital Partners sold 500,000 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $7.88M.
Adage Capital Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2016 and held it in 8 quarters.
Adage Capital Partners's Eagle Pharmaceuticals, Inc. position peaked at $11.7M in Q4 2022.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on Adage Capital Partners's 13F filing for Q4 2023, filed 14 Feb 2024.